New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:36 EDTSSNLF, MRK, BIIBMerck, Samsung Bioepis enter collaboration agreement
Merck (MRK) and Samsung Bioepis, a joint venture between Samsung (SSNLF) Biologics and Biogen (BIIB), announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Under the terms of the agreement, the companies will collaborate on clinical development, regulatory filings and manufacturing. If approved, Merck will commercialize this candidate. This collaboration builds on the agreement made by the two companies in February 2013 to develop and commercialize multiple biosimilar candidates.
News For MRK;SSNLF;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 22, 2015
15:03 EDTMRKMerck reports multiple data sets from Keytruda combination studies
Subscribe for More Information
November 20, 2015
07:17 EDTBIIB, SSNLFBiogen says Benepali receives 'positive' opinion from CHMP
Subscribe for More Information
07:00 EDTSSNLFSamsung to increase flexible OLED panel proportion, DigiTimes reports
Subscribe for More Information
06:59 EDTSSNLFReport: Samsung cuts 5,000 employees over last year, DigiTimes reports
Subscribe for More Information
November 19, 2015
07:05 EDTSSNLFNetlist parnters with Samsung for new storage class memory
Subscribe for More Information
06:34 EDTMRKEli Lilly, Merck expand immuno-oncology collaboration
Eli Lilly (LLY) and Merck (MRK) announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's Alimta and Merck's Keytruda in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer, or NSCLC. The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed. The expansion of this oncology clinical trial collaboration comes following the release of encouraging data from a Phase I study, presented earlier this year at the 16th World Congress on Lung Cancer, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
November 18, 2015
08:11 EDTMRKIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
07:01 EDTMRKThreshold enters into definitive co-promotion agreement with Merck
Threshold Pharmaceuticals (THLD) announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck (MRK) pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015. Under the commercial leadership of Merck KGaA, Darmstadt, Germany, the terms of the License and Co-Development Agreement give Threshold the right, at its own cost, to field and be responsible for its own sales force in collaboration with Merck KGaA, Darmstadt, Germany's sales force in the U.S. pursuant to the terms of the new Co-promotion Agreement. Merck KGaA, Darmstadt, Germany remains responsible for all other commercial and medical affairs functions associated with the launch and promotion of evofosfamide. The development milestone payment and royalty payment portions of the License and Co-Commercialization Agreement remain the same. To date Threshold has received upfront and milestone payments of $110 million and can earn additional potential milestone payments of up to $440M.
05:56 EDTSSNLFSony Mobile, LG to develop smartphone app processors in-house, DigiTimes says
Subscribe for More Information
05:56 EDTSSNLFReport: Samsung and LG to switch to white flip chip technology, DigiTimes says
Subscribe for More Information
November 17, 2015
08:04 EDTMRKMerck to present new KEYTRUDA findings at upcoming congresses
Merck announced that data investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, in advanced non-small cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple myeloma, and ER-positive/HER2-negative breast cancer will be presented at four medical congresses through the end of this year. In total, data from more than 30 abstracts will be presented at the Society for Melanoma Research 2015 Congress in San Francisco, Nov. 18 - 21; the 57th American Society of Hematology Annual Meeting in Orlando, Florida, Dec. 5 - 8; the San Antonio Breast Cancer Symposium, Dec. 8 - 12; and the European Society for Medical Oncology Asia 2015 Congress in Singapore, Dec. 18 - 21. By the end of 2015, data on the anti-tumor activity of KEYTRUDA will have been presented across more than 20 tumor types. "The field of immuno-oncology holds great potential across a broad spectrum of cancers," said Dr. Roy Baynes, senior vice president and head of global clinical development, Merck Research Laboratories. "Data for KEYTRUDA being presented at these scientific meetings include a first-time comparison to chemotherapy in advanced non-small cell lung cancer, novel combination data in advanced melanoma as well as first-time data in two additional tumor types, namely multiple myeloma and hormone receptor positive breast cancer, further demonstrating our deep commitment to advancing cancer treatment."
November 16, 2015
12:35 EDTSSNLFApple reaps 94% of global smartphone profits, Business Insider says
Subscribe for More Information
08:35 EDTMRKMerck to present Phase 2 hep C therapy data at The Liver Meeting
Subscribe for More Information
07:24 EDTMRKSalomon to hold a conference
Subscribe for More Information
05:57 EDTSSNLFDRAMeXchange: Q3 Mobile DRAM sales rise 18%, DigiTimes says
Mobile DRAM revenue in Q3 was up 18% sequentially to $4.55B, reports DigiTimes. According to DRAMeXchange, SK Hynix made the largest contribution to the growth with revenues surging 30.5% to $1.2B while Samsung remained the largest DRAM supplier with revenue increasing 16.5% to $2.58B. Samsung continued to hold a more than 50% share of the global mobile DRAM market in the quarter. Reference Link
05:57 EDTSSNLFReport: Samsung to shift L8 facilities to produce LTPS panels, DigiTimes reports
Subscribe for More Information
November 15, 2015
15:19 EDTMRKMerck reports integrated analysis of six trials of elbasvir/grazoprevir
Subscribe for More Information
15:15 EDTMRKMerck reports Phase 3 data on elbasvir/grazoprevir in patients injecting drugs
Subscribe for More Information
November 13, 2015
08:02 EDTMRKMerck: DMC recommends anacetrapib study continue with no changes
Subscribe for More Information
05:58 EDTSSNLFReport: Samsung stops LCD production at 1.5 fab, DigiTimes says
Samsung Display has stopped LCD production of its L5 facilities in South Korea as of October, reports DigiTimes. Citing a new report from Korea-based D-Daily, Samsung is considering whether to fully close the facilities or convert them to produce other applications. Reference Link
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use